Aldosterone and mineralocorticoid receptor action in chronic renal failure and heart failure
PDF (Español (España))


Heart Failure
Renal Insufficiency

How to Cite

Hurtado Amézquita, Y. C., Rodríguez Paéz, L. R., Tovar Cortés, H., & Révérend Lizcano, C. A. (2023). Aldosterone and mineralocorticoid receptor action in chronic renal failure and heart failure. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 10(2).


Background: The role of aldosterone and its receptor is the subject of continuous research and learning, due to its impact on pathological conditions, especially cardiac and renal conditions.

Purpose: Realize a narrative review about the renal and cardiac effect of aldosterone together with its receptor and describe the available evidence in clinical studies of drugs that have aldosterone and it´s receptor as a therapeutic target.

Methodology: In order to answer the question what are the cardiac and renal effects of aldosterone receptor activation in pathological conditions? In addition to, what implemented therapeutic strategies in randomized studies have used? A search we made in the Pubmed database with the keywords and the related Mesh terms.

Results: This review presents a wide variety of alternative action mechanisms of aldosterone and mineralocorticoid receptor and their relationship with other receptors, marking their genomic and non-genomic action, which ultimately lead to promoting inflammation and fibrosis at the cardiac level and renal. Finally, a summary of the phase II and phase III studies of aldosterone antagonists was included and discussed.

Conclusions: Aldosterone is a hormone of great relevance for its action on kidney and heart since its development, the mineralocorticoid receptor revealed as a therapeutic target in which improved drugs stand out for being more specific and for having fewer adverse effects.
PDF (Español (España))


Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, et al. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021;143(6):540-52.

Bollag W. Regulation of Aldosterone Synthesis and Secretion. Compr Physiol. 2014;4.

Ruhs S, Nolze A, Hübschmann R, Grossman C. Nongenomic effects via the mineralocorticoid receptor. J Endocrinol. 2017;234:T107-24.

Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol. 2022;18(1):56-70.

Ferreira NS, Tostes RC, Paradis P, Schiffrin EL. Aldosterone, inflammation, immune system and hypertension. Am J Hypertens. 2021;34(1):15-27.

Erraez S, López-Mesa M, Gómez-Fernández P. Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica. Nefrología. 2021;41(3):258-75.

Richardson RV, Batchen EJ, Denvir MA, Gray GA, Chapman KE. Cardiac GR and MR: From Development to Pathology. Trends Endocrinol Metab. 2016;27(1):35-43.

Deo R, Yang W, Khan AM, Bansal N, Zhang X, Leonard MB, et al. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension. 2014;64(1):103-10.

Verma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J. 2022;43(38):3781-91.

Nagase M, Ayuzawa N, Kawarazaki W, Ishizawa K, Ueda K, Yoshida S, et al. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomy-ocytes: Role of small GTPase Rac1. Hypertension. 2012;59:5006.

Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease. Nat Med. 2008;14:1370-6,

Verdugo F, Montellano F, Carreño J, Marusic E. Aplicaciones y proyecciones de los antagonistas del receptor de mineralocorticoides en el tratamiento de patologías cardiovasculares. Rev Med Chile. 2014;142:61-71.

Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84.

Veneti S, Tziomalos K. The Role of Finerenone in the Management of Diabetic Nephropathy. Diabetes Ther. 2021;12(7):1791-7.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21.

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21.

Butler J, Anstrom K, Felker M, Givertz M, Kalogeropoulos A, Konstam M, et al. Efficacy and Safety of Spironolactone in Acute Heart Failure The ATHENA-HF Randomized Clinical Trial. JAMA Cardiol. 2017;2(9):950-8.

Fu Y, Hall JE, Lu D, Lin L, Manning RD Jr, Cheng L, et al. Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. Hypertension. 2012;59:599-606.

Wang H, d’Ambrosio MA, Garvin JL, Ren Y, Carretero OA. Connecting tubule glomerular feedback in hypertension. Hypertension. 2013;62:738-45. HA.113.01846

Wang H, d’Ambrosio MA, Ren Y, Monu SR, Leung P, Kutskill K, et al. Tubuloglomerular and connecting tubuloglomerular feedback during inhibition of various Na transporters in the nephron. Am J Physiol Renal Physiol. 2015;308:F1026-31.

Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528-36.

Quach K, Lvtvyn L, Baigent C, Bueti J, Garg AX, Hawley C, et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: A systematic review and meta-analysis. Am J Kidney Dis. 2016;68:591-8.

Li Y, Xie N, Liang M. Aldosterone antagonists reduce the risk of cardiovascular mortality in dialysis patients: A meta-analysis. Evid Based Complement Alternat Med. 2019:1925243.

Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab. 2022;24(3):365-76.

Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Kim SY, et al. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J. 2016;80(5):1113-22.

Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453-63.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314(9):884-94.

Katayama S, Yamada D, Nakayama M, Yamada T, Myoishi M, Kato M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications. 2017;31(4):758-65.

Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105-14.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-29.

Pitt B, Filippatos G, Agarwal R, Anker S, Bakris G, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes; N Engl J Med. 2021;385:2252-63.

American Diabetes Association. Standards of Medical Care in Diabetes 2022. 2022;45(supl. 1):S1-2.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2023 Revista Colombiana de Endocrinología, Diabetes & Metabolismo




Download data is not yet available.